IL133225A - (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders - Google Patents
(+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disordersInfo
- Publication number
- IL133225A IL133225A IL13322598A IL13322598A IL133225A IL 133225 A IL133225 A IL 133225A IL 13322598 A IL13322598 A IL 13322598A IL 13322598 A IL13322598 A IL 13322598A IL 133225 A IL133225 A IL 133225A
- Authority
- IL
- Israel
- Prior art keywords
- norcisapride
- useful
- mediated disorders
- intestinal disorders
- treating gastro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Preparing Plates And Mask In Photomechanical Process (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97202161 | 1997-07-11 | ||
| EP98200661 | 1998-03-04 | ||
| PCT/EP1998/004193 WO1999002496A1 (en) | 1997-07-11 | 1998-07-07 | (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL133225A0 IL133225A0 (en) | 2001-03-19 |
| IL133225A true IL133225A (en) | 2005-12-18 |
Family
ID=26146686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13322598A IL133225A (en) | 1997-07-11 | 1998-07-07 | (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20030060485A1 (cs) |
| EP (1) | EP1000029B1 (cs) |
| JP (1) | JP3529102B2 (cs) |
| KR (1) | KR100358374B1 (cs) |
| CN (1) | CN1196681C (cs) |
| AT (1) | ATE251139T1 (cs) |
| AU (1) | AU757077B2 (cs) |
| BG (1) | BG64824B1 (cs) |
| BR (1) | BR9811676A (cs) |
| CA (1) | CA2292480A1 (cs) |
| CO (1) | CO4940432A1 (cs) |
| CZ (1) | CZ296212B6 (cs) |
| DE (1) | DE69818678T2 (cs) |
| DK (1) | DK1000029T3 (cs) |
| EA (1) | EA002362B1 (cs) |
| EE (1) | EE04491B1 (cs) |
| ES (1) | ES2209190T3 (cs) |
| HR (1) | HRP20000004A2 (cs) |
| HU (1) | HUP0003078A3 (cs) |
| ID (1) | ID24228A (cs) |
| IL (1) | IL133225A (cs) |
| MY (1) | MY129130A (cs) |
| NO (1) | NO315183B1 (cs) |
| NZ (1) | NZ502207A (cs) |
| PL (1) | PL190296B1 (cs) |
| PT (1) | PT1000029E (cs) |
| SK (1) | SK284941B6 (cs) |
| TR (1) | TR200000020T2 (cs) |
| TW (1) | TW553934B (cs) |
| WO (1) | WO1999002496A1 (cs) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147093A (en) * | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
| KR20010052739A (ko) | 1998-06-15 | 2001-06-25 | 더글라스이.리디치 | 무호흡증, 대식증, 다른 질환을 치료하기 위한 광학적으로순수한 (+)-노르씨사프라이드의 용도 |
| EP1464333A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
| EP1468685A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| EP1087765B1 (en) * | 1998-06-15 | 2005-03-30 | Sepracor Inc. | Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome |
| US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| HK1044277B (en) * | 1999-08-03 | 2014-02-28 | Icos Corporation | Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction |
| CA2410939C (en) * | 2000-06-07 | 2010-02-16 | Aryx Therapeutics | Materials and methods for the treatment of gastroesophageal reflux disease |
| CA2428386A1 (en) * | 2000-11-24 | 2002-05-30 | Janssen Pharmaceutica N.V. | Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage |
| KR20040045485A (ko) * | 2001-10-08 | 2004-06-01 | 썬 파마슈티컬 인더스트리스 리미티드 | 항경련제가 간격을 두고 배치된 약물전달계 |
| JP2003342186A (ja) * | 2002-05-24 | 2003-12-03 | Taisho Pharmaceut Co Ltd | 鼻炎用内服液剤組成物 |
| BRPI0506736B1 (pt) | 2004-01-07 | 2018-08-21 | Renexxion Llc | Compostos estereoisoéricos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central, e composições |
| US8524736B2 (en) | 2004-01-07 | 2013-09-03 | Armetheon, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US8138204B2 (en) | 2004-01-07 | 2012-03-20 | Aryx Therapeutics, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US20060247180A1 (en) * | 2005-04-29 | 2006-11-02 | Bergey James L | Purgative composition and uses thereof |
| JP5308818B2 (ja) | 2005-08-31 | 2013-10-09 | アルメテオン、インコーポレイテッド | 胃腸系および中枢神経系障害の治療に有用な立体異性化合物の合成方法および中間体 |
| KR20100026641A (ko) * | 2008-09-01 | 2010-03-10 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법 |
| EP3654952A1 (en) * | 2017-07-19 | 2020-05-27 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| JP2021530494A (ja) * | 2018-07-11 | 2021-11-11 | デューク・ユニヴァーシティ | 胃腸障害の治療における徐放性５−ヒドロキシトリプトファンの使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1183847A (en) * | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US4820715A (en) * | 1984-06-28 | 1989-04-11 | Bristol-Myers Company | Anti-emetic quinuclidinyl benzamides |
| NZ225152A (en) * | 1987-07-17 | 1990-04-26 | Janssen Pharmaceutica Nv | Heterocyclically substituted piperidinyl benzamides as pharmaceuticals |
| US4975439A (en) * | 1987-09-25 | 1990-12-04 | Janssen Pharmaceutical N.V. | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
| IL89848A (en) * | 1988-04-07 | 1997-08-14 | Sepracor | Chiral ester derivatives |
| TW243449B (cs) * | 1991-02-15 | 1995-03-21 | Hokuriku Pharmaceutical | |
| TW294595B (cs) * | 1992-11-20 | 1997-01-01 | Janssen Pharmaceutica Nv | |
| FR2717174B1 (fr) * | 1994-03-14 | 1996-05-31 | Sanofi Sa | Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes. |
| US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
| US6147093A (en) * | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
-
1998
- 1998-07-07 PL PL98337648A patent/PL190296B1/pl unknown
- 1998-07-07 KR KR1019997012056A patent/KR100358374B1/ko not_active Expired - Fee Related
- 1998-07-07 BR BR9811676-2A patent/BR9811676A/pt not_active Application Discontinuation
- 1998-07-07 IL IL13322598A patent/IL133225A/xx not_active IP Right Cessation
- 1998-07-07 CN CNB988069563A patent/CN1196681C/zh not_active Expired - Fee Related
- 1998-07-07 EP EP98940159A patent/EP1000029B1/en not_active Expired - Lifetime
- 1998-07-07 CA CA002292480A patent/CA2292480A1/en not_active Abandoned
- 1998-07-07 ID IDW20000033A patent/ID24228A/id unknown
- 1998-07-07 NZ NZ502207A patent/NZ502207A/en unknown
- 1998-07-07 EA EA200000057A patent/EA002362B1/ru not_active IP Right Cessation
- 1998-07-07 CZ CZ0461799A patent/CZ296212B6/cs not_active IP Right Cessation
- 1998-07-07 AU AU88575/98A patent/AU757077B2/en not_active Ceased
- 1998-07-07 WO PCT/EP1998/004193 patent/WO1999002496A1/en active IP Right Grant
- 1998-07-07 AT AT98940159T patent/ATE251139T1/de not_active IP Right Cessation
- 1998-07-07 HR HR20000004A patent/HRP20000004A2/xx not_active Application Discontinuation
- 1998-07-07 HU HU0003078A patent/HUP0003078A3/hu unknown
- 1998-07-07 EE EEP200000014A patent/EE04491B1/xx not_active IP Right Cessation
- 1998-07-07 SK SK1829-99A patent/SK284941B6/sk unknown
- 1998-07-07 PT PT98940159T patent/PT1000029E/pt unknown
- 1998-07-07 ES ES98940159T patent/ES2209190T3/es not_active Expired - Lifetime
- 1998-07-07 DK DK98940159T patent/DK1000029T3/da active
- 1998-07-07 TR TR2000/00020T patent/TR200000020T2/xx unknown
- 1998-07-07 JP JP50812899A patent/JP3529102B2/ja not_active Expired - Fee Related
- 1998-07-07 DE DE69818678T patent/DE69818678T2/de not_active Expired - Fee Related
- 1998-07-08 TW TW087111013A patent/TW553934B/zh not_active IP Right Cessation
- 1998-07-08 MY MYPI98003108A patent/MY129130A/en unknown
- 1998-07-09 CO CO98038980A patent/CO4940432A1/es unknown
-
1999
- 1999-11-30 BG BG103934A patent/BG64824B1/bg unknown
-
2000
- 2000-01-07 NO NO20000093A patent/NO315183B1/no unknown
-
2002
- 2002-09-16 US US10/244,365 patent/US20030060485A1/en not_active Abandoned
-
2004
- 2004-03-23 US US10/807,035 patent/US20040176414A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL133225A (en) | (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders | |
| MX9707980A (es) | Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos. | |
| UA29476C2 (uk) | Трансдермальна терапевтична система, що містить естрадіол | |
| RO116900B1 (ro) | Derivaţi de dihidrobenzopiran, procedeu pentru prepararea acestora, intermediar pentru realizarea procedeului, compoziţie farmaceutică şi metodă de tratament | |
| CA2272584A1 (en) | Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases | |
| IS1904B (is) | Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum | |
| HU9601857D0 (en) | New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them | |
| CA2180535A1 (en) | A method for treatment of psoriasis, by omeprazole or related compounds | |
| ZA961074B (en) | Chiral Methylphenyloxazolidinones. | |
| MY116593A (en) | Process for the preparation of o-demethyltramadol enantiomers | |
| AU2102497A (en) | Resolution of threo-methylphenidate | |
| SI1274685T1 (sl) | Derivat piridin-1-oksida in postopek njegove transformacije v farmacevtsko ucinkovite sestavine | |
| GR3024592T3 (en) | Process for preparing and resolving 2-phenyl-3-aminopiperidine | |
| CA2282279A1 (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions | |
| AU6851396A (en) | Novel fused isoquinolines as dopamine receptor ligands | |
| CA2296560A1 (en) | Amino acid derivatives useful to treat stroke | |
| ZA976854B (en) | Treatment of psychotic disorders. | |
| EP0804186A4 (en) | INDOLDITERPEN ALKALOIDS | |
| ZA973156B (en) | Process for the production of enantiomerically-pure azetidine-2-carboxylic acid. | |
| HUP9901713A3 (en) | Process for the production of enantiomerically-pure azetidine-2-carboxylic acid | |
| MY101747A (en) | Dihydroorotic acids derivative, processes for preparing the same | |
| MX9704704A (es) | Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion. | |
| PL352119A1 (en) | Derivatives of aminotetraline for treatment of cardiovascular diseases | |
| IL116262A0 (en) | Processes for preparing ranitidine | |
| MX9704621A (es) | Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su preparacion, medicamentos que contienen estos compuestos, y su utilizacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |